Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory
By David L. Paterson, W. Ko, A. von Gottberg, J. Casellas, L. Mulazımoglu, K. Klugman, Robert A. Bonomo, L. Rice, J. McCormack, V. Yu. Journal of Clinical Microbiology, 2001
600 citations recorded by the source corpus.
Subfields: Clinical Biochemistry, Epidemiology, Molecular Medicine
View Paper: https://www.semanticscholar.org/paper/b851e05834bbb3781fa094a65c289da86d877ad7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Biochemistry
In Epidemiology
In Molecular Medicine
Citations in the corpus
- Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. (2015, background): “…caused by ESBL-producing organisms with extended-spectrum cephalosporins or aztreonam may result in treatment failure even when the causative organisms appear to be susceptible to these antimicrobial agents by routine susceptibility testing (Paterson and Bonomo, 2005; Paterson et al., 2001).”
- Global Challenge of Multidrug-Resistant Acinetobacter baumannii (2007, background): “and Klebsiella pneumoniae, the class A ESBLs in an AmpC background are associated with clinical failure when cefepime is used for treatment despite in vitro susceptibility to that agent (143, 198).”
- Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (2008, background): “The most active agents are the carbapenems (Level II) (267).”